chartexchange

ATXI
AVENUE THERAPEUTICS INC
stockOTC

EODNov 12, 2026
0.28USD-8.291%(-0.03)2,828
Loading…
Loading…
575,098
Healthcare
Biotechnology
HQ
Tampa, FL, USA
Previous Close
$0.31
Beta
1.01
52-Week High
$0.96 2025-12-02
52-Week Low
$0.15 2026-02-24
SMA 50
$0.43
SMA 200
$0.47
Avg. Vol 10D
2,793
Avg. Vol 30D
8,427
Avg. Vol 90D
6,006
Relative Vol
0.34
2.85M
Apr 26, 2024 · 1-for-75 (reverse)
ATXI Profile

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.

ATXI Performance
PeriodPriceDateChangeBeta
1W0.312026-11-09-8.29%0.000
1M0.402026-10-20-30.73%-1.368
3M0.262026-08-14+8.70%0.736
6M0.312026-05-18-9.62%0.577
1Y0.802025-11-17-65.00%1.006
2Y1.902024-11-18-85.26%—
5Y1,530.002021-11-17-99.98%0.006
ATXI Stock Summary

AVENUE THERAPEUTICS INC (OTC:ATXI) stock price today is $0.28, and today's volume is 2,828. ATXI is down 8.291% today. The 30 day average volume is 8,427. ATXI market cap is $575,098 with 2.05M shares outstanding.